Retinopathy in systemic lupus erythematosus: pathogenesis and approach to therapy (Q33706460)

28 July 2017

1 reference

title

Retinopathy in systemic lupus erythematosus: pathogenesis and approach to therapy (English)

1 reference

systemic lupus erythematosus

28 July 2017

main subject

1 reference

Giorgi D

1

1 reference

28 July 2017

Pace F

2

1 reference

28 July 2017

Giorgi A

3

1 reference

28 July 2017

Bonomo L

4

1 reference

28 July 2017

Gabrieli CB

5

1 reference

28 July 2017

publication date

1 August 1999

1 reference

28 July 2017

1 reference

28 July 2017

volume

60

1 reference

28 July 2017

issue

8

1 reference

28 July 2017

page(s)

688-696

1 reference

Thrombosis, abortion, cerebral disease, and the lupus anticoagulant

28 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0198-8859%2899%2900035-X

7 January 2021

Anticardiolipin antibodies: detection by radioimmunoassay and association with thrombosis in systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1016%2FS0198-8859%2899%2900035-X

7 January 2021

The syndrome of thrombosis, thrombocytopenia, and recurrent spontaneous abortions associated with antiphospholipid antibodies: Hughes syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0198-8859%2899%2900035-X

7 January 2021

Hughes' syndrome: the antiphospholipid syndrome. A historical view

1 reference

https://api.crossref.org/works/10.1016%2FS0198-8859%2899%2900035-X

7 January 2021

Anticardiolipin cofactor(s) and differential diagnosis of autoimmune disease

1 reference

https://api.crossref.org/works/10.1016%2FS0198-8859%2899%2900035-X

7 January 2021

Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor

1 reference

https://api.crossref.org/works/10.1016%2FS0198-8859%2899%2900035-X

7 January 2021

Anti-phospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: beta 2-glycoprotein I (apolipoprotein H)

1 reference

https://api.crossref.org/works/10.1016%2FS0198-8859%2899%2900035-X

7 January 2021

The antiphospholipid syndrome: ten years on.

1 reference

https://api.crossref.org/works/10.1016%2FS0198-8859%2899%2900035-X

7 January 2021

Clinical manifestations and management of the antiphospholipid syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0198-8859%2899%2900035-X

7 January 2021

Arterial disease and thrombosis in the antiphospholipid syndrome: a pathogenic role for endothelin 1

1 reference

https://api.crossref.org/works/10.1016%2FS0198-8859%2899%2900035-X

7 January 2021

The management of thrombosis in the antiphospholipid-antibody syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0198-8859%2899%2900035-X

7 January 2021

A retrospective review of 61 patients with antiphospholipid syndrome. Analysis of factors influencing recurrent thrombosis

1 reference

https://api.crossref.org/works/10.1016%2FS0198-8859%2899%2900035-X

7 January 2021

Lupus anticoagulant and thrombosis in systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1016%2FS0198-8859%2899%2900035-X

7 January 2021

Lupus anticoagulant: an analysis of the clinical and laboratory features of 219 cases

1 reference

https://api.crossref.org/works/10.1016%2FS0198-8859%2899%2900035-X

7 January 2021

Thrombosis in systemic lupus erythematosus. Relation to the presence of circulating anticoagulants

1 reference

https://api.crossref.org/works/10.1016%2FS0198-8859%2899%2900035-X

7 January 2021

Antiphospholipid antibodies: a risk factor for occlusive ocular vascular disease in systemic lupus erythematosus and the 'primary' antiphospholipid syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0198-8859%2899%2900035-X

7 January 2021

Retinal and choroidal vaso-occlusive disease in systemic lupus erythematosus associated with antiphospholipid antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS0198-8859%2899%2900035-X

7 January 2021

Antiphospholipid antibodies and retinal vascular disease

1 reference

https://api.crossref.org/works/10.1016%2FS0198-8859%2899%2900035-X

7 January 2021

Vaso-occlusive retinopathy: is it a classical clinical manifestation of the antiphospholipid syndrome?

1 reference

https://api.crossref.org/works/10.1016%2FS0198-8859%2899%2900035-X

7 January 2021

Optic neuropathy in systemic lupus erythematosus and antiphospholipid syndrome (APS): clinical features, pathogenesis, review of the literature and proposed ophthalmological criteria for APS diagnosis

1 reference

https://api.crossref.org/works/10.1016%2FS0198-8859%2899%2900035-X

7 January 2021

Ocular findings in systemic lupus erythematosus.

1 reference

https://api.crossref.org/works/10.1016%2FS0198-8859%2899%2900035-X

7 January 2021

SLE retinopathy: evaluation by fluorescein angiography

1 reference

https://api.crossref.org/works/10.1016%2FS0198-8859%2899%2900035-X

7 January 2021

Disseminated lupus erythematosus; analysis of thirty-four cases

1 reference

https://api.crossref.org/works/10.1016%2FS0198-8859%2899%2900035-X

7 January 2021

Cerebral and retinal vascular changes in systemic lupus erythematosus.

1 reference

https://api.crossref.org/works/10.1016%2FS0198-8859%2899%2900035-X

7 January 2021

Severe retinal vaso-occlusive disease in systemic lupus erythematous

1 reference

https://api.crossref.org/works/10.1016%2FS0198-8859%2899%2900035-X

7 January 2021

Retinopathy in systemic lupus erythematosus: relationship to disease activity

1 reference

https://api.crossref.org/works/10.1016%2FS0198-8859%2899%2900035-X

7 January 2021

The investigation of patients with retinal vascular occlusion

1 reference

https://api.crossref.org/works/10.1016%2FS0198-8859%2899%2900035-X

7 January 2021

Accelerated atherosclerosis and coronary disease in SLE.

1 reference

https://api.crossref.org/works/10.1016%2FS0198-8859%2899%2900035-X

7 January 2021

Atherosclerosis in SLE and Hughes syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0198-8859%2899%2900035-X

7 January 2021

The atherogenic effect of lupus sera: Systemic lupus erythematosus-derived immune complexes stimulate the accumulation of cholesterol in cultured smooth muscle cells from human aorta

1 reference

https://api.crossref.org/works/10.1016%2FS0198-8859%2899%2900035-X

7 January 2021

Crossreaction between antibodies to oxidised low-density lipoprotein and to cardiolipin in systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1016%2FS0198-8859%2899%2900035-X

7 January 2021

Antiphospholipid antibodies and atherosclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0198-8859%2899%2900035-X

7 January 2021

Antiphospholipid antibodies and myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0198-8859%2899%2900035-X

7 January 2021

Atherosclerosis and the antiphospholipid syndrome: a link unravelled?

1 reference

https://api.crossref.org/works/10.1016%2FS0198-8859%2899%2900035-X

7 January 2021

The anti-phospholipid (Hughes) syndrome: a crossroads of autoimmunity and atherosclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0198-8859%2899%2900035-X

7 January 2021

Vasculitis in systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1016%2FS0198-8859%2899%2900035-X

7 January 2021

Vasculitis in systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1016%2FS0198-8859%2899%2900035-X

7 January 2021

A point prevalence study of 150 patients with idiopathic retinal vasculitis: 2. Clinical relevance of antiretinal autoimmunity and circulating immune complexes

1 reference

https://api.crossref.org/works/10.1016%2FS0198-8859%2899%2900035-X

7 January 2021

Anticardiolipin antibodies in isolated retinal vasculitis

1 reference

https://api.crossref.org/works/10.1016%2FS0198-8859%2899%2900035-X

7 January 2021

Retinal Microangiopathy in Systemic Lupus Erythematosus

1 reference

https://api.crossref.org/works/10.1016%2FS0198-8859%2899%2900035-X

7 January 2021

10.1016/S0198-8859(99)00035-X

Identifiers

DOI

1 reference

28 July 2017

1 reference